Chapter

Biochemical markers of bone metabolism in CKD

Pablo Ureña, Klaus Olgaard and Kevin Martin

in The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease

Second edition

Published on behalf of Oxford University Press

Published in print June 2010 | ISBN: 9780199559176
Published online November 2012 | e-ISBN: 9780191753350 | DOI: http://dx.doi.org/10.1093/med/9780199559176.003.011

Series: Oxford Clinical Nephrology Series

Biochemical markers of bone metabolism in CKD

Show Summary Details

Preview

In the absence of bone biopsy, there is no ideal marker of bone remodeling in CKD patients. Recent studies have shown that PTH alone is not necessarily a good biomarker for bone turnover in the setting of CKD, particularly when the levels are modestly increased (3–9 times the upper limit of normal). As such, increased plasma PTH levels are not always synonymous of high turnover bone disease and vice versa. Other bone biomarkers discussed in this chapter provide useful information at the extremes but each one alone is not more valuable that PTH, particularly at distinguishing low from normal bone turnover. The combined use of PTH with some of the more accessible biomarkers of bone remodeling have the potential to improve the diagnosis, monitoring, and treatment monitoring of CKD-MBD in the future. However, further studies are clearly required to examine the utility of these biomarkers and their correlations with bone histology in the current era.

Chapter.  11453 words.  Illustrated.

Subjects: Rheumatology ; Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.